Stereotactic ablative radiotherapy (SABR) has been recognized as a standard alternative treatment to surgery for inoperable early stage non-small cell lung cancer (NSCLC). Guaranteed local control rates over 90% makes oncologists wonder whether SABR is qualified enough to challenge surgery in operable patients. The role of SABR for centrally located lesions would be another question because of the increased risk of severe toxic effect. Plenty of studies suggest that optimization of dose regimen and appropriate case selection would be helpful.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qPd9BM
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
A host of new therapies are now available for treating patients with chronic lymphocytic leukemia (CLL) in both the upfront and relapsed or ...
-
Related Articles Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch. 2017...
-
Abstract Background The role of thymectomy in the treatment of juvenile myasthenia gravis (JMG) is poorly defined. The objective of this...
-
Biomarker testing is recommended for all patients diagnosed with non–small cell lung cancer. At a minimum, testing should include the mutati...
-
Early Antarctic ice age dynamics Antarctica. Image courtesy of Wikimedia Commons/Dave Pape. The extent of Antarctic ice sheets oscillated wi...
-
http://ift.tt/2rdV14q
-
American Thyroid Resarch Grant to Nikita Pozdeyev, MD, PhD, University of Colorado Newswise (press release) The 2016 Research Grant h...
-
We thank Liu et al. (1) for their comments on our paper (2). The first point of Liu et al. (1) is that the Lake Dali Early Holocene highstan...
-
In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer, among adjuvant radiotherapy options for whole-brea...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου